![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Sun Pharmaceutical Industries Limited Mumbai In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Amisulpride, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2009-246 - Rev 01
This Chemical Type CEP, issued on July 01, 2016, remains in force until July 12, 2021, ensuring its reliability within the pharmaceutical industry.
Substance Number 1490 associated with this CEP further emphasizes